– USA, CA – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David Johnson to its board of directors.
Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical industry.
“David has an impressive record of successfully building commercial infrastructure and launching new medicines for patients,” said CEO, Dr. Rachel Haurwitz. “We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we continue to build our company and advance our pipeline of chRDNA-edited allogeneic cell therapies for patients with hematologic and solid tumors.”
About David Johnson
Mr. Johnson currently serves as CCO of Global Blood Therapeutics where he leads the global commercial functions that he built and which facilitated the launch of Oxbryta in 2019. Previously, Mr. Johnson spent 15 years at Gilead Sciences, Inc., where he held roles of increasing responsibility in the company’s commercial organization. He was instrumental in the commercial launch of Gilead’s hepatitis C treatments Sovaldi, Harvoni, Epclusa, and Vosevi, and its hepatitis B treatment Vemlidy. As VP, of sales and marketing, for Gilead’s Antiviral Business Unit, he launched the HIV treatments Complera and Stribild. Before Gilead, Mr. Johnson had an 11-year tenure at Glaxo Smith Kline, where he held various positions in sales, product marketing, business development, global commercial strategy, and portfolio development.
“Caribou is making its mark as a leader in the allogeneic cell therapy field, deploying its differentiated chRDNA technology to create off-the-shelf cell therapies that may reach greater numbers of patients globally than autologous cell therapies,” said David Johnson. “I look forward to working with the Caribou leadership team and other board members as the company develops and advances its pipeline.”
Mr. Johnson earned an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina and a B.A. in business marketing from the University of Puget Sound.
About Caribou’s Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high-efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.
For more information: https://www.cariboubio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.